MIMEDX GROUP, INC. Form 8-K April 22, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

Date of Report (date of earliest event reported): April 22, 2013

MIMEDX GROUP, INC.

(Exact name of registrant as specified in charter)

Florida 000-52491 26-2792552
(State or other jurisdiction of (Commission File Number) incorporation)

60 Chastain Center Blvd., Suite 60 30144
Kennesaw, GA (Zip Code)
(Address of principal executive offices)

(678) 384-6720 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: MIMEDX GROUP, INC. - Form 8-K

Item 8.01 Other Events

On April 22, MiMedx Group, Inc., ("MiMedx" or the "Company") issued a press release announcing that The NASDAQ Capital Market had approved the Company's application to have its common stock listed for trading under the symbol "MDXG" on The NASDAQ Capital Market, effective as of the beginning of trading on April 25, 2013. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits

(c) Exhibits

Exhibit

No. Description

99.1 MiMedx Group, Inc. Press Release, dated April 22, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MIMEDX GROUP, INC.

Dated: April 22, 2013 By: /s/: Michael J. Senken

Michael J. Senken, Chief Financial Officer

2